State-of-the-art pharmacotherapy for diabetic neuropathy.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human data
PubMed 32866410 · doi:10.1080/14656566.2020.1812578
What was done
The authors reviewed pharmacological management and therapeutic strategies for diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN), evaluating multifactorial risk factor modification (glycemia, lipids, blood pressure), FDA-approved symptomatic therapies, and emerging pathogenetic treatments.
What was found
No quantitative trial data, effect sizes, or statistical metrics are reported in the abstract. The authors note that DPN and AN affect ~50% of patients with diabetes. FDA-approved symptomatic options for painful DPN remain limited to pregabalin, duloxetine, and tapentadol. There are no FDA-approved disease-modifying treatments for diabetic neuropathy.
Why it matters
It emphasizes the persistent lack of disease-modifying pharmacotherapy for diabetic neuropathy, keeping clinical practice focused on metabolic risk factor management and symptom palliation.
Limits
This is a narrative review representing expert opinion without a systematic search strategy, explicit study selection criteria, or meta-analysis. The abstract provides no primary data, sample sizes, effect estimates, or comparative safety analyses.
Cited by
- supports There are no FDA-approved drugs in the United States to treat the underlying nerve degeneration and loss in diabetic neuropathy.